DOJ and DEA Announce Marijuana Rescheduling Actions

Certain medical marijuana products moved to Schedule III as broader review begins. The Justice Department (DOJ) and Drug Enforcement Administration (DEA) announced that FDA-approved products containing marijuana—along with…

Read More

NIH Study Reveals Effectiveness of Coordinated Care 

The trial in community health centers showed reduced blood pressure in clinics. A clinical trial funded by the National Institutes of Health (NIH) found that a team-based treatment…

Read More

President Trump Orders FDA to Expedite Psychedelic Drug Reviews

Ibogaine compounds have been studied as potential therapies for treating mental health. President Donald Trump ordered the Food and Drug Administration to expedite and prioritize reviews of research…

Read More

U.S. Airlifts Medical Supplies to Venezuela

Shipment supports interim health authorities amid stabilization effort. President Trump’s administration directed an airlift of more than 6,000 kilograms of medical supplies to Venezuela as part of a…

Read More

Transportation Department Expands Drone Testing Locations

FAA designates new sites to support unmanned aircraft integration. The Department of Transportation (DOT) and the Federal Aviation Administration (FAA) announced two new Unmanned Aircraft Systems (UAS) test…

Read More

HHS and DEA Extend Telemedicine Prescribing Flexibilities Through 2026

Temporary extension maintains access to certain controlled medications. The Department of Health and Human Services (HHS), in coordination with the Drug Enforcement Administration (DEA), announced a fourth temporary…

Read More

FDA Approves Gene Therapy for Treating Spinal Muscular Atrophy

Patients of all ages now have access to care for the rare genetic disease. The Food and Drug Administration (FDA) has announced approval for Itvisma (onasemnogene abeparvovec-brve), which…

Read More

FDA Adds Warning and Restrictions to Duchenne Gene Therapy

Updated labeling limits treatment to ambulatory children after reports of fatal liver failure in non-ambulatory patients. The U.S. Food and Drug Administration (FDA) has approved significant labeling changes…

Read More

FDA Drafts New Guidance for the Development of Affordable Biosimilar Drugs

The new guidance seeks to lower development costs and improve patient access to safe, effective alternatives to high-cost biologic medicines. The U.S. Food and Drug Administration (FDA) recently…

Read More

President Trump Plans New Tariffs for Several Industries

The president highlights the compromising of national security by foreign trade practices and the need to protect U.S. manufacturing from “unfair outside competition.“ President Donald Trump announced a…

Read More
Back to top
FE3